News

Novel optogenetics gene therapies for patients with blinding diseases

News

Biotech Startup Ray Raises $100M for Vision-Restoring Gene Therapies

May 19, 2023

Ray Therapeutics Closes Series A Financing to Advance Therapeutics in Clinical Development

May 18, 2023

Series A backers see Ray of hope; $100M for retinal diseases

May 18, 2023

Ray: a Genotype-Agnostic Approach to Reversing Blindness With One-Time Therapy

May 18, 2023

SF Business Times: Inspired by founder’s daughter, East Bay startup Ray Therapeutics raises $100M to tackle eye diseases

May 17, 2023

WSJ: Ray Therapeutics Tackles a Rare Blinding Disease With $100 Million in Financing

May 16, 2023

Press Releases

Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases

Funds will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases….

May 16, 2023

Ray Therapeutics to Present at Upcoming Scientific Conferences

We’re delighted to present our data which shows the power of visual optogenetics as a disruptive technology with the potential to restore vision to…

April 11, 2023

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Building on AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray Therapeutics’ gene therapy for patients living…

October 10, 2022

Ray Therapeutics Appoints Dr. Peter Francis as Chief Scientific & Medical Officer and Jenny Holt as SVP, Program Portfolio Management

Dr. Francis is a world-renowned clinician scientist and a leader in gene therapy drug development….

September 6, 2022